|
Total
|
po
|
756
|
5.0 (2.0–11.0)
|
10.60 (9.68–11.59)
|
0.87 (0.82–0.92)
|
|
iv
|
1800
|
5.0 (2.0–9.0)
|
8.28 (7.88–8.71)
|
1.03 (0.99–1.06)
|
|
Antibacterials
|
|
Combinations of penicillins, incl. Beta-lactamase inhibitors (J01CR)
|
po
|
9
|
3.0 (2.5–11.5)
|
8.00 (1.94–30.36)
|
0.65 (0.34–1.06)
|
|
iv
|
180
|
4.0 (2.0–8.0)
|
7.43 (6.34–8.69)
|
1.04 (0.93–1.15)
|
|
Second-generation cephalosporins (J01DC)
|
po
|
8
|
4.5 (1.5–9.0)
|
6.95 (3.85–12.12)
|
1.79 (0.83–3.20)
|
|
iv
|
56
|
3.0 (1.0–5.8)
|
5.16 (3.86–6.82)
|
1.06 (0.85–1.30)
|
|
Third-generation cephalosporins (J01DD)
|
po
|
93
|
3.0 (1.0–7.0)
|
7.06 (5.47–9.06)
|
0.90 (0.77–1.05)
|
|
iv
|
138
|
4.0 (2.0–7.0)
|
7.23 (6.01–8.66)
|
1.02 (0.89–1.15)
|
|
Fourth-generation cephalosporins (J01DE)
|
po
|
1
|
–
|
–
|
–
|
|
iv
|
83
|
5.0 (2.0–11.0)
|
8.24 (6.73–10.02)
|
1.19 (0.999–1.40)
|
|
Carbapenems (J01DH)
|
po
|
0
|
–
|
–
|
–
|
|
iv
|
190
|
5.0 (2.0–9.0)
|
8.63 (7.37–10.08)
|
1.03 (0.92–1.14)
|
|
Combinations of sulfonamides and trimethoprim, incl. Derivatives (J01EE)
|
po
|
112
|
8.5 (4.0–21.0)
|
17.57 (13.98–21.94)
|
0.89 (0.77–1.01)
|
|
iv
|
14
|
3.0 (1.8–4.0)
|
3.65 (2.54–5.15)
|
1.75 (1.12–2.48)
|
|
Other aminoglycosides (J01GB)
|
po
|
3
|
–
|
–
|
–
|
|
iv
|
143
|
7.0 (3.0–11.0)
|
9.64 (8.35–11.09)
|
1.27 (1.12–1.43)
|
|
Fluoroquinolones (J01MA)
|
po
|
232
|
4.0 (2.0–8.0)
|
7.62 (6.52–8.89)
|
0.92 (0.83–1.01)
|
|
iv
|
95
|
4.0 (2.0–7.0)
|
7.00 (5.72–8.53)
|
1.14 (0.97–1.33)
|
|
Glycopeptide antibacterials (J01XA)
|
po
|
10
|
7.0 (2.0–10.3)
|
13.15 (4.90–33.47)
|
0.79 (0.47–1.18)
|
|
iv
|
353
|
5.0 (2.0–10.0)
|
8.69 (7.82–9.63)
|
1.10 (1.01–1.18)
|
|
Polymyxins (J01XB)
|
po
|
0
|
–
|
–
|
–
|
|
iv
|
83
|
3.0 (1.0–6.0)
|
6.25 (5.07–7.64)
|
1.26 (1.05–1.49)
|
|
Other antibacterials (J01XX)
|
po
|
9
|
10.0 (5.5–12.0)
|
10.06 (6.65–14.84)
|
2.07 (1.13–3.27)
|
|
iv
|
39
|
3.0 (1.0–7.0)
|
7.75 (4.92–11.98)
|
0.86 (0.66–1.09)
|
|
Antimycotics
|
|
Antibiotics (J02AA)
|
po
|
3
|
–
|
–
|
–
|
|
iv
|
154
|
5.0 (2.0–9.3)
|
9.00 (7.45–10.82)
|
0.94 (0.83–1.05)
|
|
Triazole derivatives (J02AC)
|
po
|
88
|
9.5 (3.0–23.0)
|
19.11 (14.82–24.44)
|
0.94 (0.79–1.11)
|
|
iv
|
59
|
5.0 (2.0–18.0)
|
13.06 (9.27–18.17)
|
0.83 (0.68–1.01)
|
|
Other antimycotics for systemic use (J02AX)
|
po
|
2
|
–
|
–
|
–
|
|
iv
|
82
|
5.0 (3.0–11.0)
|
10.84 (8.42–13.86)
|
0.96 (0.81–1.12)
|
